Rheumatology

The approvals were based on results from the JUNIPERA trial, which showed secukinumab reduced the risk of flare and disease activity when compared with placebo over 2 years in pediatric patients with ERA and JPsA.

"The challenges of an existing rheumatologist workforce shortage, changing workforce demographics, and physician burnout have been compounded by the COVID-19 pandemic."

Take 5 minutes to catch up on Rheumatology Network's highlights from the week ending June 25, 2022.

Teodora Staeva, PhD, discusses how Lupus Research Alliance's is recognizing the critical contributions of underrepresented minority researchers through their Diversity in Lupus Research Award.

"Remote care interventions have become more widespread over the past 20 years, with presumed benefits for diagnosis, treatment, rehabilitation and follow-up monitoring of patients.”

SLE-dysregulated genes were linked to biological functions and gene networks, including regulation of type I interferon-mediated signaling pathway, response to steroid hormone, and response to hypoxia.

The complete ACR manuscript is available to elaborate on the earlier summary of antirheumatic medication for patients who are undergoing total hip or total knee anthroplasty.

The American College of Rheumatology (ACR)/American Association of Hip and Knee Surgeons (AAHKS) has published guidance regarding perioperative management of antirheumatic medication in patients with rheumatic diseases undergoing elective total hip or total knee arthroplasty.

Investigators identified novel biomarkers of incident gout and replicated novel metabolomic biomarkers of gout, including plasma levels of glycoprotein acetyls.

Test your knowledge of the treatment and management of rheumatoid arthritis with our latest RA quizzes.

Do you know the latest recommendations for managing patients with rheumatoid arthritis who have not achieved target with disease-modifying antirheumatic drugs (DMARDs)? Take this quiz to find out.

Community rheumatology practices are finding it increasingly difficult to source vital therapies and supplies to care for patients.

Vigorous physical activity may reduce the risk of non-communicable diseases, including rheumatoid arthritis and gout.

Take 5 minutes to catch up on Rheumatology Network's highlights from the week ending June 19, 2022.

“The COVID-19 pandemic causes concern among patients with ARD due to increased risk of infection and heightened isolation from social distancing,” investigators explained.

The study, which assessed data from the JUVE-BASIS trial, suggests baricitinib significantly reduced both the time to and frequency of flares in patients with JIA when compared with placebo.

The utility of calculating interferon scores in SLE has generated considerable discourse amongst rheumatologists.

Differences among baseline clinical and laboratory characteristics between cases and controls were observed in those with a presence of subcutaneous tophi and higher serum urate levels.

Désirée van der Heijde, MD, PhD, explains the results of a recent trial evaluating the safety and efficacy of bimekizumab in patients with active ankylosing spondylitis.

Rheumatoid arthritis impacts men and women differently. How much do you know about the differences between the sexes? Take this quiz to find out.

The use of biological DMARDs was similar across countries, but in less wealthy countries, more patients with moderate/high disease activity were not receiving biologics.

Take 5 minutes to catch up on Rheumatology Network's highlights from the week ending June 11, 2022.

Nihar Bhakta, MD, explains Familial Mediterranean Fever, a rare rheumatic disease, and how Aristea Therapeutics is working to treat patients suffering from this condition.

Frédéric Lavie, MD, PhD, explains the results of the data presented at EULAR evaluating guselkumab for the treatment of psoriatic arthritis.

Terence Rooney, MD, explains the innovative research methods that Janssen utilizes and the benefits of precision medicine in the treatment of psoriatic arthritis.

Terence Rooney, MD, discusses recent findings indicating that guselkumab provided patients with psoriatic arthritis with sustained improvements in health-related quality of life through 2 years.

Karin Schenck-Gustafsson, MD, PhD, FESC, explains why sex and gender must be taken into account when treating and managing patients with rheumatic disease from a cardiologist's perspective.

Line Uhrenholt, MD, discusses the results of her randomized, open-label, equivalence trial study evaluating disease activity-guided tapering of biologics in patients with inflammatory arthritis.

Findings suggested that actigraphy may provide additional information to self-reported sleep measures in patients with rheumatoid arthritis.

Investigators believe that treatment escalation within patients with rheumatoid arthritis should utilize interventions beyond the traditional physician-patient relationship.